BACKGROUND: We sought to define the utilization and effect of adjuvant external-beam radiotherapy (XRT) on patients having undergone curative-intent resection for gallbladder cancer (GBC). METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified 5,011 patients with GBC who underwent resection between 1988 and 2009. The impact of XRT on survival was analyzed by the use of propensity-score matching by comparing clinicopathologic factors between patients who received resection only versus resection plus XRT. RESULTS: Median age was 72 years, and most patients were female (73.4%); 66.2% patients had intermediate to poorly differentiated tumors, and 19.1% had lymph node metastasis. The majority (75.0%) had "localized" disease by Surveillance, Epidemiology, and End Results classification. A total of 899 patients (17.9%) received XRT whereas 4,112 patients did not. Factors associated with receipt of XRT were younger age (odds ratio [OR] 5.33), tumor extension beyond the serosa (OR 1.55), intermediate- to poorly differentiated tumors (OR 1.56), and lymph node metastasis (OR 2.59) (all P < .05). Median and 1-year survival were 15 months and 59.0%, respectively. On propensity-matched multivariate model, despite having more advanced tumors, XRT was independently associated with better long-term survival at 1 year (hazard ratio 0.45; P < .001), but not 5 years (hazard ratio 1.06; P = .50). CONCLUSION: A total of 18% of patients with GBC received XRT after curative intent surgery. The use of adjuvant XRT was associated with a short-term survival benefit, but the benefit dissipated over time.
BACKGROUND: We sought to define the utilization and effect of adjuvant external-beam radiotherapy (XRT) on patients having undergone curative-intent resection for gallbladder cancer (GBC). METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified 5,011 patients with GBC who underwent resection between 1988 and 2009. The impact of XRT on survival was analyzed by the use of propensity-score matching by comparing clinicopathologic factors between patients who received resection only versus resection plus XRT. RESULTS: Median age was 72 years, and most patients were female (73.4%); 66.2% patients had intermediate to poorly differentiated tumors, and 19.1% had lymph node metastasis. The majority (75.0%) had "localized" disease by Surveillance, Epidemiology, and End Results classification. A total of 899 patients (17.9%) received XRT whereas 4,112 patients did not. Factors associated with receipt of XRT were younger age (odds ratio [OR] 5.33), tumor extension beyond the serosa (OR 1.55), intermediate- to poorly differentiated tumors (OR 1.56), and lymph node metastasis (OR 2.59) (all P < .05). Median and 1-year survival were 15 months and 59.0%, respectively. On propensity-matched multivariate model, despite having more advanced tumors, XRT was independently associated with better long-term survival at 1 year (hazard ratio 0.45; P < .001), but not 5 years (hazard ratio 1.06; P = .50). CONCLUSION: A total of 18% of patients with GBC received XRT after curative intent surgery. The use of adjuvant XRT was associated with a short-term survival benefit, but the benefit dissipated over time.
Authors: T Todoroki; K Ohara; T Kawamoto; N Koike; S Yoshida; H Kashiwagi; M Otsuka; K Fukao Journal: Int J Radiat Oncol Biol Phys Date: 2000-02-01 Impact factor: 7.038
Authors: D González González; J P Gerard; A W Maners; B De la Lande-Guyaux; A Van Dijk-Milatz; J H Meerwaldt; J F Bosset; J D Van Dijk Journal: Semin Liver Dis Date: 1990-05 Impact factor: 6.115
Authors: John J Kresl; Steven E Schild; George T Henning; Leonard L Gunderson; John Donohue; Henry Pitot; Michael G Haddock; David Nagorney Journal: Int J Radiat Oncol Biol Phys Date: 2002-01-01 Impact factor: 7.038
Authors: Skye C Mayo; Andrew D Shore; Hari Nathan; Barish Edil; Christopher L Wolfgang; Kenzo Hirose; Joseph Herman; Richard D Schulick; Michael A Choti; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2010-09-08 Impact factor: 3.452
Authors: J F Bosset; G Mantion; M Gillet; E Pelissier; M Boulenger; P Maingon; O Corbion; S Schraub Journal: Cancer Date: 1989-11-01 Impact factor: 6.860
Authors: Yuhree Kim; Neda Amini; Ana Wilson; Georgios A Margonis; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Kenneth Cardona; Shishir K Maithel; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2016-05-11 Impact factor: 5.344
Authors: Richard S Hoehn; Koffi Wima; Audrey E Ertel; Alexandra Meier; Syed A Ahmad; Shimul A Shah; Daniel E Abbott Journal: J Gastrointest Surg Date: 2015-08-21 Impact factor: 3.452
Authors: Gaya Spolverato; Yuhree Kim; Aslam Ejaz; Vicente Valero; Malcolm H Squires; George Poultsides; Ryan C Fields; Mark Bloomston; Sharon M Weber; Alexandra W Acher; Konstantinos Votanopoulos; Carl Schmidt; Clifford S Cho; Shishir K Maithel; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2014-06-10 Impact factor: 3.452
Authors: Kota Sahara; Diamantis I Tsilimigras; Shishir K Maithel; Daniel E Abbott; George A Poultsides; Ioannis Hatzaras; Ryan C Fields; Matthew Weiss; Charles Scoggins; Chelsea A Isom; Kamran Idrees; Perry Shen; Itaru Endo; Timothy M Pawlik Journal: J Surg Oncol Date: 2020-01-06 Impact factor: 2.885